Chardan Capital analyst Keay Nakae maintained a Buy rating on Better Therapeutics, Inc. (BTTX – Research Report) yesterday and set a price target of $9.00. The company’s shares closed yesterday at $0.79.
According to TipRanks, Nakae is a 2-star analyst with an average return of 0.0% and a 38.54% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Seres Therapeutics, Avidity Biosciences, and Pear Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Better Therapeutics, Inc. with a $7.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Better Therapeutics, Inc.’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.77 million. In comparison, last year the company had a GAAP net loss of $41.08 million
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BTTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mountain Crest Acquisition Corp II is a blank check company.
Read More on BTTX:
- Is BTTX a Buy, Before Earnings?
- Galera Therapeutics expands commercial leadership team
- Fly Insider: Better Therapeutics, AMD among week’s notable insider transactions
- Better Therapeutics price target lowered to $5 from $6 at Lake Street
- Better Therapeutics directors buy $500K, CEO buys $200K in common stock
